Clinical trials: Congestive Cardiac Failure
Congestive Heart Failure
Safety Trial of OPC-61815 Injection in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake
To confirm the tolerability of intravenous administration of OPC-61815 at 8 or 16 mg once daily for a maximum of 5 days to CHF patients with volume overload despite having received diuretics (injection) other than vasopressin…
- Trial name
- NCT03962101
- Testing
- OPC-61815 injection
- Where
- Japan
- Volunteers
- 45 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Congestive Heart Failure
Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure
To confirm the non-inferiority of OPC-61815 16-mg injection to tolvaptan 15-mg tablet using as the primary endpoint the change in body weight following 5-day intravenous administration of OPC-61815 16-mg injection or 5-day oral…
- Trial name
- NCT03772041
- Testing
- OPC-61815, Tolvaptan Tab 15 MG
- Where
- Japan
- Volunteers
- 294 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.